Araştırma Makalesi

DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE

Cilt: 50 Sayı: 3 19 Eylül 2026
PDF İndir
EN TR

DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE

Öz

Objective: In this study, eight new 4-methylthiazole derivatives were designed and synthesized with the aim of exhibiting multi-target effects in the treatment of Alzheimer's disease. Their cholinesterase inhibitor activities, antioxidant properties, and metal chelator effects were tested in vitro.

Material and Method: The title compounds were obtained using 4-methylthiazole-2-amine as the starting material. According to method A, intermediate 1 was synthesized by reacting the starting material with 3-chloropropionyl chloride. Subsequently, the title compounds (2a-f) were obtained via substitution reactions with suitable amine derivatives. The title compounds that could not be obtained by method A were prepared from the reaction of starting material with appropriate propanoic acid derivatives using method B. Structural analysis of the synthesized and purified final compounds were elucidated using 1H-NMR, 13C-NMR, and HRMS methods. The cholinesterase inhibitor effects of all synthesized compounds were determined using the modified Ellman method. Additionally, the antioxidant properties of all the compounds were measured using the DPPH and ORAC methods, and their metal-chelator effects were analysed using UV spectroscopy.

Result and Discussion: The cholinesterase inhibitory effects of all title compounds were evaluated, and compounds 2c, 2f, and 3b were determined to be selective butyrylcholinesterase (BChE) inhibitors. Specifically, the 4-fluorobenzylpiperazine derivative compound 2c (IC50=8.96 μM) is the most potent selective BChE inhibitor in the series. In addition, all final compounds exhibit antioxidant properties according to the ORAC test. Also, all compounds chelate with different amounts of Cu(II), Fe(II), and Zn(II) ions.

Anahtar Kelimeler

Destekleyen Kurum

Biruni University Scientific Project

Proje Numarası

BIRUNI-BAP-01-2023-01-31

Etik Beyan

The author declares that the ethics committee approval is not required for this study.

Teşekkür

This study was supported by the Biruni University Scientific Project [grant number BIRUNI-BAP-01-2023-01-31]. Prof. Dr. Deniz S. Doğruer is gratefully acknowledged for her support, encouragement, and expert advice throughout this research.

Kaynakça

  1. 1. Alzheimer’s Association. (2025) 2025 Alzheimer’s disease facts and figures. Alzheimers Dement, 21(5). [CrossRef]
  2. 2. Hampel, H., Mesulam, M.M., Cuello, A.C., et al. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 141(7), 1917-1933. [CrossRef]
  3. 3. Cho, H.-J., Sharma, A.K., Zhang, Y., et al. (2020). A multifunctional chemical agent as an attenuator of amyloid burden and neuroinflammation in Alzheimer’s disease. ACS Chemical Neuroscience, 11(10), 1471-1481. [CrossRef]
  4. 4. Scheltens, P., De Strooper, B., Kivipelto, M., et al. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577-1590.
  5. 5. Dorababu, A. (2022). Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer’s drug design and discovery. European Journal of Pharmacology, 920 (174847). [CrossRef]
  6. 6. Luo, K., Chen, J., Li, H., et al. (2023). Design, synthesis and biological evaluation of new multi-target scutellarein hybrids for treatment of Alzheimer’s disease. Bioorganic Chemistry, 138(106596). [CrossRef]
  7. 7. Li, Q., Xiong, B., Wang, Y., et al. (2022). A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement. European Journal of Medicinal Chemistry, 239(114510). [CrossRef]
  8. 8. Li, Q., Yang, H., Chen, Y., et al. (2017). Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer’s disease. European Journal of Medicinal Chemistry, 132(294-309). [CrossRef]

Ayrıntılar

Birincil Dil

İngilizce

Konular

Farmasotik Kimya

Bölüm

Araştırma Makalesi

Erken Görünüm Tarihi

9 Eylül 2026

Yayımlanma Tarihi

19 Eylül 2026

Gönderilme Tarihi

27 Ekim 2025

Kabul Tarihi

5 Ağustos 2026

Yayımlandığı Sayı

Yıl 2026 Cilt: 50 Sayı: 3

Kaynak Göster

APA
Bardakkaya, M. (2026). DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE. Journal of Faculty of Pharmacy of Ankara University, 50(3), 717-727. https://doi.org/10.33483/jfpau.1810037
AMA
1.Bardakkaya M. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE. Ankara Ecz. Fak. Derg. 2026;50(3):717-727. doi:10.33483/jfpau.1810037
Chicago
Bardakkaya, Merve. 2026. “DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE”. Journal of Faculty of Pharmacy of Ankara University 50 (3): 717-27. https://doi.org/10.33483/jfpau.1810037.
EndNote
Bardakkaya M (01 Eylül 2026) DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE. Journal of Faculty of Pharmacy of Ankara University 50 3 717–727.
IEEE
[1]M. Bardakkaya, “DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE”, Ankara Ecz. Fak. Derg., c. 50, sy 3, ss. 717–727, Eyl. 2026, doi: 10.33483/jfpau.1810037.
ISNAD
Bardakkaya, Merve. “DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE”. Journal of Faculty of Pharmacy of Ankara University 50/3 (01 Eylül 2026): 717-727. https://doi.org/10.33483/jfpau.1810037.
JAMA
1.Bardakkaya M. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE. Ankara Ecz. Fak. Derg. 2026;50:717–727.
MLA
Bardakkaya, Merve. “DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE”. Journal of Faculty of Pharmacy of Ankara University, c. 50, sy 3, Eylül 2026, ss. 717-2, doi:10.33483/jfpau.1810037.
Vancouver
1.Merve Bardakkaya. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW MULTI-TARGET 4-METHYLTHIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER’S DISEASE. Ankara Ecz. Fak. Derg. 01 Eylül 2026;50(3):717-2. doi:10.33483/jfpau.1810037

Kapsam ve Amaç

Ankara Üniversitesi Eczacılık Fakültesi Dergisi, açık erişim, hakemli bir dergi olup Türkçe veya İngilizce olarak farmasötik bilimler alanındaki önemli gelişmeleri içeren orijinal araştırmalar, derlemeler ve kısa bildiriler için uluslararası bir yayım ortamıdır. Bilimsel toplantılarda sunulan bildiriler supleman özel sayısı olarak dergide yayımlanabilir. Ayrıca, tüm farmasötik alandaki gelecek ve önceki ulusal ve uluslararası bilimsel toplantılar ile sosyal aktiviteleri içerir.